| Aspira Womens Health is engaged in the discovery, development and commercialization of diagnostic and bio-analytical solutions. Co.'s products and related services include: OVA1, a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at high risk of having a malignant ovarian tumor prior to planned surgery; Overa, a biomarker panel; OVA1PLUS, a service offering combining its OVA1 and Overa products; and ASPiRA GenetiX, a genetic test for women's health diseases, which is focused on detecting hereditary breast and ovarian cancer syndrome; and Carrier screening, genetic screening for carriers of disease. The AWH YTD return is shown above.
The YTD Return on the AWH YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AWH YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AWH YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.